Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2023 18:01 ET | Source: Theralase Technologies Inc.

Theralase® Releases FY2022 Audited Financial Statements

TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
February 23, 2023 07:00 ET | Source: Theralase Technologies Inc.

Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium

TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
February 21, 2023 07:35 ET | Source: Theralase Technologies Inc.

Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Company

TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
February 02, 2023 07:00 ET | Source: Theralase Technologies Inc.

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
January 25, 2023 07:00 ET | Source: Theralase Technologies Inc.

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
January 05, 2023 18:17 ET | Source: Theralase Technologies Inc.

Theralase ® Announces Warrant Extension

TORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and...
November 29, 2022 18:43 ET | Source: Theralase Technologies Inc.

Theralase Releases Q322 Interim Financial Statements

TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
November 21, 2022 07:00 ET | Source: Theralase Technologies Inc.

Theralase® Grants Stock Options

TORONTO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
November 17, 2022 17:24 ET | Source: Theralase Technologies Inc.

Theralase ® Closes Private Placement Equity Financing

TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
October 03, 2022 07:00 ET | Source: Theralase Technologies Inc.

Theralase® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing

Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”)...

Next Page keyboard_arrow_right